145 related articles for article (PubMed ID: 37566974)
1. Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies.
Bhattacharjee U; Jandial A; Singh C; Lekshmon KS; Mishra K; Sandal R; Nampoothiri R; Naseem S; Suri V; Jain A; Lad DP; Prakash G; Khadwal A; Malhotra P
Leuk Res; 2023 Oct; 133():107367. PubMed ID: 37566974
[TBL] [Abstract][Full Text] [Related]
2. Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution.
R C; Malik PS; Sahoo RK; Sharawat S; Singh M; Garg V; Bhatia K; Kantak A; Kumar S; Kumar L
Ann Hematol; 2023 Aug; 102(8):2087-2096. PubMed ID: 37322094
[TBL] [Abstract][Full Text] [Related]
3. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience.
Assi R; Kantarjian H; Keating M; Pemmaraju N; Verstovsek S; Garcia-Manero G; Ravandi F; Borthakur G; Dahl J; Jabbour E; Cortes JE
Leuk Lymphoma; 2021 Apr; 62(4):909-917. PubMed ID: 33283580
[TBL] [Abstract][Full Text] [Related]
4. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
Dou X; Qin Y; Huang X; Jiang Q
Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy Outcomes in Chronic Myeloid Leukemia: A Single Center Experience.
Madabhavi I; Sarkar M; Modi M; Kadakol N
J Glob Oncol; 2019 Sep; 5():1-11. PubMed ID: 31584851
[TBL] [Abstract][Full Text] [Related]
6. Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Tiribelli M; Latagliata R; Breccia M; Capodanno I; Miggiano MC; Cavazzini F; Bucelli C; Attolico I; Crescenzi SL; Russo S; Annunziata M; Sorà F; Bonifacio M; Mulas O; Loglisci G; Maggi A; Binotto G; Crisà E; Scortechini AR; Leporace AP; Sancetta R; Murgano P; Abruzzese E; Stagno F; Rapezzi D; Luzi D; Vincelli I; Bocchia M; Fava C; Malato A; Crugnola M; Pizzuti M; Lunghi F; Galimberti S; Dalmazzo M; Fanin R; Scalzulli E; Foà R; Iurlo A; Saglio G; Specchia G
Cancer; 2023 Sep; 129(17):2637-2644. PubMed ID: 37354090
[TBL] [Abstract][Full Text] [Related]
7. [Treatment status of tyrosine kinase inhibitors in Chinese patients with chronic myeloid leukemia in 2020].
Wang HF; Zhang YL; Liu XL; Zhu HL; Liang R; Liu BC; Zhou L; Meng L; Li WM; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):535-542. PubMed ID: 34455739
[No Abstract] [Full Text] [Related]
8. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
9. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
11. [Fertility and disease outcomes in patients with chronic myeloid leukemia].
Dou XL; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):980-985. PubMed ID: 32023726
[No Abstract] [Full Text] [Related]
12. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
13. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Ota S; Matsukawa T; Yamamoto S; Ito S; Shindo M; Sato K; Kondo T; Kohda K; Sakai H; Mori A; Takahashi T; Ikeda H; Kuroda H; Haseyama Y; Yamamoto M; Sarashina T; Yoshida M; Kobayashi R; Nishio M; Ishihara T; Hirayama Y; Kakinoki Y; Kobayashi H; Fukuhara T; Imamura M; Kurosawa M
Eur J Haematol; 2018 Jul; 101(1):95-105. PubMed ID: 29660177
[TBL] [Abstract][Full Text] [Related]
14. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
16. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Survival of Patients with Chronic Myeloid Leukemia Treated with Imatinib in the Last 15 Years in Lebanon.
Massoud M; Sakr R; Kerbage F; Makdissi J; Hawi J; Rached L; Nasr F; Chahine G
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S111-S115. PubMed ID: 28760296
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
Nishiyama-Fujita Y; Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto K; Fujita H; Fujioka I; Tsuchiya S; Kimura Y; Iwanaga E; Komatsu N; Asou N; Kizaki M; Hatta Y; Kawaguchi T
Ann Med; 2022 Dec; 54(1):1244-1254. PubMed ID: 35486442
[TBL] [Abstract][Full Text] [Related]
19. Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review.
Rambhatla A; Strug MR; De Paredes JG; Cordoba Munoz MI; Thakur M
J Assist Reprod Genet; 2021 Aug; 38(8):1897-1908. PubMed ID: 33826052
[TBL] [Abstract][Full Text] [Related]
20. [Combination of socio-demographic and clinical co-variates for predicting treatment responses and outcomes in patients with chronic myeloid leukemia in the chronic phase].
Zhang XS; Qin YZ; Lai YY; Shi HX; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):54-62. PubMed ID: 35231994
[No Abstract] [Full Text] [Related]
[Next] [New Search]
